ETH Zurich Spin-Off aiNET Founded at D-BSSE
aiNET leverages artificial intelligence and large-scale networks to help pharmaceutical industries and biotechs discover biologics from big data. Its algorithms analyse antibody repertoire sequencing data and help select large-molecules that bind to cancer, infectious and autoimmune targets.
The technology was developed in the Laboratory for Systems and Synthetic Immunology of Prof. Sai T. Reddy at the Department of Biosystems Science and Engineering in Basel, where aiNET is located. aiNET is the 25th ETH spin-off founded in 2017.
The D-BSSE had a central role in supporting research projects that developed further into commercially viable concepts. This effort involved several years, multiple projects and a team of postdocs, doctorate and master students from the Prof. Reddy group (Victor Greiff, Enkelejda Miho, Cédric Weber, Vendi Grobelsek, Alex Yermanos, Simon Friedensohn) collaborating closely with the ETH Scientific IT Services teams lead by Thomas Wüst and Matthew Baker (Laurenczy Balazs, Juan Mariano Fuentes Serna, Rok Roskar, Manuel Kohler).
The incorporation of aiNET was made possible by the kind support of the ETH Foundation and the Pioneer Fellowship that allowed to develop the research work into a commercial minimal product, the help of ETH Transfer (Marjan Kraak, Emanuel Weber) and with the business support of the ETH Innovation and Entrepreneurship Lab (ieLab coach Dragan Grabulovski, marketing Sybille Zimmermann).
The Swiss company aiNET is currently discussing projects with large pharmaceutical companies globally.
For more information please visit: external pagewww.ainet.ch